Merck's Belzutifan Combination Approved by FDA for Adjuvant Treatment of Renal Cell Carcinoma
MT Newswires Live
Jun 13
Merck's (MRK) Belzutifan in combination with pembrolizumab has been approved for the adjuvant treatment of adults with renal cell carcinoma, the US Food and Drug Administration said Friday.
It is also approved for the combination with pembrolizumab and berahyaluronidase alfa-pmph, the FDA said.
The treatment is for patients with a clear cell component at intermediate to high risk of recurrence following nephrectomy, or after nephrectomy and resection of metastatic lesions, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.